Stock in focus: Investors distrust Novo Nordisk's future plans
The manufacturer of weight loss injections and global market leader for insulin products is looking far into the future. But that's not enough for investors. A major competitor is doing better.
Novo Nordisk's capital market day in London last Monday sparked intense discussion on international digital stock forums. The Danish pharmaceutical company announced plans to launch over five new blockbuster medications by 2030, expecting to generate over 20 billion euros in revenue by 2035. The company also presented research data on Cagri-Sema, a new weight loss medication showing higher weight loss than existing treatments, with a US approval decision expected in the fourth quarter of this year.
Despite this, the company's stock lost around 10 percent of its value last week, as investors sought more details and revenue forecasts. Some analysts, including those at Jefferies and Deutsche Bank, subsequently lowered their price targets.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
